002082 ST万邦
已收盘 09-11 15:00:00
资讯
新帖
简况
股市必读：ST万邦新发布《关于回购公司股份的进展公告》
证券之星 · 09-04
股市必读：ST万邦新发布《关于回购公司股份的进展公告》
ST万邦（002082）披露关于公司股票交易被实施其他风险警示相关事项的进展及风险提示公告，9月2日股价下跌2.46%
证券之星 · 09-02
ST万邦（002082）披露关于公司股票交易被实施其他风险警示相关事项的进展及风险提示公告，9月2日股价下跌2.46%
ST万邦（002082）2026年中报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 08-28
ST万邦（002082）2026年中报简析：营收净利润同比双双增长，盈利能力上升
ST万邦（002082）披露关于非标准审计意见涉及事项自查进展暨股票可能被叠加实施其他风险警示的提示公告，8月27日股价下跌2.5%
证券之星 · 08-27
ST万邦（002082）披露关于非标准审计意见涉及事项自查进展暨股票可能被叠加实施其他风险警示的提示公告，8月27日股价下跌2.5%
ST万邦(002082)6月30日股东户数1.77万户，较上期减少62.43%
证券之星 · 08-27
ST万邦(002082)6月30日股东户数1.77万户，较上期减少62.43%
ST万邦2026年半年报：降本增效推动扭亏，资金占用仍存隐忧
蓝鲸财经 · 08-27
ST万邦2026年半年报：降本增效推动扭亏，资金占用仍存隐忧
图解ST万邦中报：第二季度单季净利润同比下降2182.22%
证券之星 · 08-27
图解ST万邦中报：第二季度单季净利润同比下降2182.22%
股市必读：ST万邦新发布《关于子公司WP107药品多剂量爬坡临床研究获得伦理批件的公告》
证券之星 · 08-20
股市必读：ST万邦新发布《关于子公司WP107药品多剂量爬坡临床研究获得伦理批件的公告》
ST万邦（002082）披露子公司WP107药品多剂量爬坡临床研究获得伦理批件的公告，8月18日股价下跌6.19%
证券之星 · 08-18
ST万邦（002082）披露子公司WP107药品多剂量爬坡临床研究获得伦理批件的公告，8月18日股价下跌6.19%
ST万邦(002082.SZ)子公司WP107药品多剂量爬坡临床研究获得伦理批件
智通财经 · 08-18
ST万邦(002082.SZ)子公司WP107药品多剂量爬坡临床研究获得伦理批件
股市必读：ST万邦新发布《关于子公司产品石杉碱甲注射液中选省际联盟采购的公告》
证券之星 · 08-13
股市必读：ST万邦新发布《关于子公司产品石杉碱甲注射液中选省际联盟采购的公告》
ST万邦（002082）披露子公司石杉碱甲注射液中选省际联盟采购公告，8月11日股价上涨3.14%
证券之星 · 08-11
ST万邦（002082）披露子公司石杉碱甲注射液中选省际联盟采购公告，8月11日股价上涨3.14%
ST万邦(002082.SZ)子公司产品石杉碱甲注射液中选省际联盟采购
智通财经 · 08-11
ST万邦(002082.SZ)子公司产品石杉碱甲注射液中选省际联盟采购
股市必读：ST万邦新发布《关于回购公司股份的进展公告》
证券之星 · 08-06
股市必读：ST万邦新发布《关于回购公司股份的进展公告》
ST万邦（002082）披露关于公司股票交易被实施其他风险警示相关事项的进展及风险提示公告，8月4日股价下跌0.1%
证券之星 · 08-04
ST万邦（002082）披露关于公司股票交易被实施其他风险警示相关事项的进展及风险提示公告，8月4日股价下跌0.1%
ST万邦（002082）披露子公司药品获得《药品注册证书》公告，7月27日股价上涨0.77%
证券之星 · 07-27
ST万邦（002082）披露子公司药品获得《药品注册证书》公告，7月27日股价上涨0.77%
ST万邦（002082）披露股票交易异常波动公告，7月23日股价下跌6.39%
证券之星 · 07-23
ST万邦（002082）披露股票交易异常波动公告，7月23日股价下跌6.39%
7月23日ST万邦（002082）龙虎榜数据：机构净买入734.93万元（3日）
证券之星 · 07-23
7月23日ST万邦（002082）龙虎榜数据：机构净买入734.93万元（3日）
ST万邦（002082）披露控股股东及实际控制人部分股份质押公告，7月22日股价下跌7.55%
证券之星 · 07-22
ST万邦（002082）披露控股股东及实际控制人部分股份质押公告，7月22日股价下跌7.55%
ST万邦（002082）披露子公司WP107药品多剂量爬坡临床研究获得FDA许可的公告，7月16日股价下跌4.07%
证券之星 · 07-16
ST万邦（002082）披露子公司WP107药品多剂量爬坡临床研究获得FDA许可的公告，7月16日股价下跌4.07%
加载更多
公司概况
公司名称：
万邦德医药控股集团股份有限公司
所属行业：
医药制造业
上市日期：
2006-11-20
主营业务：
万邦德医药控股集团股份有限公司的主营业务是集医药制造和医疗器械研发、生产、销售于一体。公司的主要产品是医药制造、医疗器械。
发行价格：
6.36
{"stockData":{"symbol":"002082","market":"SZ","secType":"STK","nameCN":"ST万邦","latestPrice":8.98,"timestamp":1789110213000,"preClose":9.19,"halted":0,"volume":7960500,"delay":0,"changeRate":-0.0229,"floatShares":568000000,"shares":612000000,"eps":-0.192,"marketStatus":"已收盘","change":-0.21,"latestTime":"09-11 15:00:00","open":9.1,"high":9.12,"low":8.8,"amount":71002200,"amplitude":0.0348,"askPrice":8.98,"askSize":501,"bidPrice":8.97,"bidSize":5,"shortable":0,"etf":0,"ttmEps":-0.192,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":9.19,"symbolType":"stock","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":9.65,"lowLimit":8.73,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":611689055,"isCdr":false,"pbRate":2.18,"roa":"--","roe":"2.49%","epsLYR":-0.27,"committee":-0.394754,"marketValue":5493000000,"turnoverRate":0.014,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-14。","floatMarketCap":5099000000},"requestUrl":"/m/hq/s/002082","defaultTab":"news","newsList":[{"id":"2664401805","title":"股市必读：ST万邦新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664401805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664401805?lang=zh_cn&edition=full","pubTime":"2026-09-04 01:20","pubTimestamp":1788456023,"startTime":"0","endTime":"0","summary":"截至2026年8月31日，公司尚未开始实施股份回购。关于公司股票交易被实施其他风险警示相关事项的进展及风险提示公告万邦德医药控股集团股份有限公司因2025年度内部控制被北京德皓国际会计师事务所出具否定意见审计报告，公司股票交易被实施其他风险警示。经自查，认定控股股东及关联方资金占用余额合计9,490.96万元，控股股东承诺于2026年9月27日前归还。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400001903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0004","002082","BK0050","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810547","title":"ST万邦（002082）披露关于公司股票交易被实施其他风险警示相关事项的进展及风险提示公告，9月2日股价下跌2.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810547","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664810547?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:43","pubTimestamp":1788360193,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，ST万邦报收于9.11元，较前一交易日下跌2.46%，最新总市值为55.72亿元。近日，万邦德医药控股集团股份有限公司发布《关于公司股票交易被实施其他风险警示相关事项的进展及风险提示公告》。公告显示，公司因2025年度内部控制被北京德皓国际会计师事务所出具否定意见审计报告，股票交易被实施其他风险警示。经自查，认定控股股东及关联方资金占用余额合计9,490.96万元，控股股东承诺于2026年9月27日前归还。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200043191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002082","BK0050","BK0004","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662396880","title":"ST万邦（002082）2026年中报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662396880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662396880?lang=zh_cn&edition=full","pubTime":"2026-08-28 06:26","pubTimestamp":1787869563,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期ST万邦发布2026年中报。截至本报告期末，公司营业总收入5.89亿元，同比上升1.77%，归母净利润6327.72万元，同比上升369.99%。本报告期ST万邦盈利能力上升，毛利率同比增幅37.82%，净利率同比增幅538.62%。财报体检工具显示：建议关注公司现金流状况建议关注公司债务状况本文数据来源于ST万邦2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800011292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749705","title":"ST万邦（002082）披露关于非标准审计意见涉及事项自查进展暨股票可能被叠加实施其他风险警示的提示公告，8月27日股价下跌2.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662749705?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:23","pubTimestamp":1787826190,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，ST万邦报收于9.77元，较前一交易日下跌2.5%，最新总市值为59.76亿元。该股当日开盘10.01元，最高10.05元，最低9.64元，成交额达1.57亿元，换手率为2.83%。近日，ST万邦发布《关于对2025年度非标准审计意见涉及事项自查进展暨公司股票可能被叠加实施其他风险警示的提示公告》。公告显示，万邦德医药控股集团股份有限公司因2025年度内部控制被出具否定意见审计报告，公司股票已于2026年5月6日起被实施其他风险警示。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700044338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002082","BK0050","BK0004","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662035867","title":"ST万邦(002082)6月30日股东户数1.77万户，较上期减少62.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662035867","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662035867?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:06","pubTimestamp":1787825219,"startTime":"0","endTime":"0","summary":"证券之星消息，近日ST万邦披露，截至2026年6月30日公司股东户数为1.77万户，较3月31日减少2.94万户，减幅为62.43%。在中药行业个股中，ST万邦股东户数低于行业平均水平，截至6月30日，中药行业平均股东户数为5.18万户。从股价来看，2026年3月31日至2026年6月30日，ST万邦区间跌幅为65.17%，在此期间股东户数减少2.94万户，减幅为62.43%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700043139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0050","002082","BK0028","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662727219","title":"ST万邦2026年半年报：降本增效推动扭亏，资金占用仍存隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2662727219","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662727219?lang=zh_cn&edition=full","pubTime":"2026-08-27 12:20","pubTimestamp":1787804427,"startTime":"0","endTime":"0","summary":"财报数据显示，报告期公司实现营业收入5.89亿元，同比增长1.77%；归母净利润6327.72万元，同比增长369.99%；归属于上市公司股东的扣除非经常性损益的净利润6219.77万元，同比扭亏为盈，上年同期为亏损2411.43万元。业绩大幅扭亏并高增的核心原因在于销售费用的显著压降，报告期销售费用为5950.43万元，同比下降36.65%，主要系药品集采后公司优化营销团队、调整营销策略所致。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787795063123825145","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0004","BK0239","BK0028","002082","BK0050"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749520","title":"图解ST万邦中报：第二季度单季净利润同比下降2182.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749520","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662749520?lang=zh_cn&edition=full","pubTime":"2026-08-27 02:20","pubTimestamp":1787768414,"startTime":"0","endTime":"0","summary":"证券之星消息，ST万邦2026年中报显示，上半年度公司主营收入5.89亿元，同比上升1.77%；归母净利润6327.72万元，同比上升369.99%；扣非净利润6219.77万元，同比上升357.93%；其中2026年第二季度，公司单季度主营收入2.15亿元，同比下降18.54%；单季度归母净利润-3967.33万元，同比下降2182.22%；单季度扣非净利润-4066.62万元，同比下降150.89%；负债率39.65%，投资收益310.96万元，财务费用2366.38万元，毛利率44.85%。财报数据概要请见下图:本文数据来源于ST万邦2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700006812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660442776","title":"股市必读：ST万邦新发布《关于子公司WP107药品多剂量爬坡临床研究获得伦理批件的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660442776","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660442776?lang=zh_cn&edition=full","pubTime":"2026-08-20 02:02","pubTimestamp":1787162542,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司WP107药品多剂量爬坡临床研究获伦理批件，正式进入I期临床研究阶段。公司公告汇总关于子公司WP107药品多剂量爬坡临床研究获得伦理批件的公告万邦德医药控股集团股份有限公司全资子公司万邦德制药集团有限公司自主研发的WP107药品，针对重症肌无力适应症，在健康试验参与者中开展的多剂量爬坡临床试验研究已获得温州医科大学附属第二医院医学伦理委员会批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","002082","BK0028","BK0239","BK0050"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498794","title":"ST万邦（002082）披露子公司WP107药品多剂量爬坡临床研究获得伦理批件的公告，8月18日股价下跌6.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660498794?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:10","pubTimestamp":1787062232,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，ST万邦报收于10.01元，较前一交易日下跌6.19%，最新总市值为61.23亿元。近日，万邦德医药控股集团股份有限公司全资子公司万邦德制药集团有限公司自主研发的WP107药品，针对重症肌无力适应症，在健康试验参与者中开展的多剂量爬坡临床试验研究已获得温州医科大学附属第二医院医学伦理委员会批准。全球重症肌无力治疗市场预计持续增长，WP107有望成为适合长期服用且对吞咽困难患者友好的新治疗选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800042294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0050","002082","BK0028","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660450928","title":"ST万邦(002082.SZ)子公司WP107药品多剂量爬坡临床研究获得伦理批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2660450928","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660450928?lang=zh_cn&edition=full","pubTime":"2026-08-18 15:44","pubTimestamp":1787039081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST万邦 发布公告，公司全资子公司万邦德制药集团有限公司自主研发的治疗全身型重症肌无力的新药WP107，拟在健康试验参与者中开展的多剂量爬坡临床试验研究获得了温州医科大学附属第二医院/温州医科大学附属育英儿童医院医学伦理委员会的审查批件，批准项目开展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002082","BK0050","BK0004","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659011979","title":"股市必读：ST万邦新发布《关于子公司产品石杉碱甲注射液中选省际联盟采购的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659011979","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659011979?lang=zh_cn&edition=full","pubTime":"2026-08-13 01:01","pubTimestamp":1786554075,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，ST万邦报收于11.18元，上涨3.23%，换手率3.0%，成交量17.05万手，成交额1.93亿元。公司公告汇总：全资子公司万邦德制药石杉碱甲注射液中选由河南省牵头的34种药品省际联盟集中带量采购，采购周期2年，覆盖全国多个省区市。石杉碱甲注射液为公司核心独家剂型产品，是国内首创药物，拥有多个国家奖项和专利，且为唯一生产厂家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300000868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","002082","BK0028","BK0239","BK0050"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658699956","title":"ST万邦（002082）披露子公司石杉碱甲注射液中选省际联盟采购公告，8月11日股价上涨3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658699956","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658699956?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:39","pubTimestamp":1786441189,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，ST万邦报收于10.83元，较前一交易日上涨3.14%，最新总市值为66.25亿元。近日，ST万邦披露《关于子公司产品石杉碱甲注射液中选省际联盟采购的公告》。公告显示，公司全资子公司万邦德制药集团有限公司参加由河南省牵头的34种药品省际联盟集中带量采购，其产品石杉碱甲注射液按规则一中选。石杉碱甲注射液为公司核心独家剂型产品，是国内首创药物，拥有多个国家奖项和专利，且为唯一生产厂家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100028566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002082","BK0004","BK0050"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993812","title":"ST万邦(002082.SZ)子公司产品石杉碱甲注射液中选省际联盟采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993812","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658993812?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:20","pubTimestamp":1786436410,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST万邦(002082.SZ)发布公告，公司全资子公司万邦德制药集团有限公司参加了由河南省牵头，对34种药品开展省际联盟集中带量采购工作的投标工作，根据“34种药品省际联盟采购办公室”于2026年8月10日发布的《34种药品省际联盟采购公告(八)》，公司产品石杉碱甲注射液中选本次采购。据悉，石杉碱甲注射液适用于良性记忆障碍，提高患者指向记忆、联想学习、图像回忆、无意义图形再认及人像回忆等能力;对痴呆患者和脑器质性病变引起的记忆障碍。此次中选，有利于锁定联盟内公立医院约定采购量，进一步扩大中选产品的销售规模，提升石杉碱甲注射液在认知障碍、重症肌无力治疗领域的全国市场占有率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0004","BK0239","BK0050","BK0028","002082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657952482","title":"股市必读：ST万邦新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657952482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657952482?lang=zh_cn&edition=full","pubTime":"2026-08-06 02:01","pubTimestamp":1785952902,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，ST万邦报收于10.26元，上涨2.7%，换手率2.28%，成交量12.95万手，成交额1.31亿元。截至2026年7月31日，公司尚未开始实施股份回购。关于公司股票交易被实施其他风险警示相关事项的进展及风险提示公告万邦德医药控股集团股份有限公司因2025年度内部控制被年审机构出具否定意见审计报告，公司股票交易被实施其他风险警示。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","BK0239","002082","BK0050","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656706552","title":"ST万邦（002082）披露关于公司股票交易被实施其他风险警示相关事项的进展及风险提示公告，8月4日股价下跌0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656706552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656706552?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:39","pubTimestamp":1785854354,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，ST万邦报收于9.99元，较前一交易日下跌0.1%，最新总市值为61.11亿元。该股当日开盘10.02元，最高10.25元，最低9.91元，成交额达9861.14万元，换手率为1.73%。近日，万邦德医药控股集团股份有限公司发布《关于公司股票交易被实施其他风险警示相关事项的进展及风险提示公告》。公告显示，公司因2025年度内部控制被年审机构出具否定意见审计报告，股票交易被实施其他风险警示。公司生产经营正常，提醒投资者注意风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0004","BK0239","002082","BK0050"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654045272","title":"ST万邦（002082）披露子公司药品获得《药品注册证书》公告，7月27日股价上涨0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654045272","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654045272?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:17","pubTimestamp":1785161837,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘，ST万邦报收于9.12元，较前一交易日上涨0.77%，最新总市值为55.79亿元。该股当日开盘8.73元，最高9.12元，最低8.53元，成交额达1.23亿元，换手率为2.44%。近日，万邦德医药控股集团股份有限公司全资子公司万邦德制药集团有限公司收到国家药品监督管理局核准签发的舒必利片《药品注册证书》，药品通用名称为舒必利片，剂型为片剂，规格0.1g，注册分类为化学药品3类，批准文号为国药准字H20265261。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700034787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0050","BK0004","002082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653726652","title":"ST万邦（002082）披露股票交易异常波动公告，7月23日股价下跌6.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653726652","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653726652?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:13","pubTimestamp":1784815995,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，ST万邦报收于8.94元，较前一交易日下跌6.39%，最新总市值为54.69亿元。该股当日开盘9.41元，最高9.51元，最低8.65元，成交额达2.15亿元，换手率为4.23%。近日，ST万邦发布《关于股票交易异常波动的公告》。公告显示，公司股票连续3个交易日内收盘价格跌幅偏离值累计超过20%，属于股票交易异常波动。公司股票自2026年5月6日起被实施其他风险警示，因2025年度财务报告被出具保留意见，内部控制被出具否定意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300047947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0050","BK0004","BK0028","002082","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653574638","title":"7月23日ST万邦（002082）龙虎榜数据：机构净买入734.93万元（3日）","url":"https://stock-news.laohu8.com/highlight/detail?id=2653574638","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653574638?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:01","pubTimestamp":1784800879,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月23日公布的交易公开信息显示，ST万邦因连续三个交易日内，跌幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月23日收盘，ST万邦报收于8.94元，下跌6.39%，换手率4.23%，成交量24.01万手，成交额2.15亿元。从龙虎榜公布的三日买卖数据来看，机构合计净买入734.93万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300037080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0050","BK0028","BK0004","002082","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653765238","title":"ST万邦（002082）披露控股股东及实际控制人部分股份质押公告，7月22日股价下跌7.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653765238","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653765238?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:11","pubTimestamp":1784729479,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，ST万邦报收于9.55元，较前一交易日下跌7.55%，最新总市值为58.42亿元。该股当日开盘10.08元，最高10.59元，最低9.43元，成交额达1.53亿元，换手率为2.68%。近日，ST万邦发布《关于控股股东及实际控制人部分股份质押的公告》。公告显示，控股股东万邦德集团、实际控制人赵守明及庄惠将其持有的部分股份质押，合计质押10,300,000股，占公司总股本1.68%。控股股东及其一致行动人累计质押股份占其所持股份比例超过80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002082","BK0004","BK0050","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651428390","title":"ST万邦（002082）披露子公司WP107药品多剂量爬坡临床研究获得FDA许可的公告，7月16日股价下跌4.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651428390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651428390?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:25","pubTimestamp":1784211918,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，ST万邦报收于11.3元，较前一交易日下跌4.07%，最新总市值为69.12亿元。近日，万邦德医药控股集团股份有限公司全资子公司万邦德制药集团有限公司自主研发的WP107获得美国FDA批准，同意开展用于健康试验参与者的多剂量爬坡临床试验研究。该药品适应症为全身型重症肌无力，已获FDA孤儿药认定，并先后获得中美临床试验许可。FDA认可中国多剂量爬坡研究数据对全球研发的支持作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600040248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","BK0239","002082","BK0028","BK0050"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789299730900,"stockEarnings":[{"period":"1week","weight":-0.0313},{"period":"1month","weight":-0.1968},{"period":"3month","weight":-0.2403},{"period":"6month","weight":-0.5149},{"period":"1year","weight":-0.092},{"period":"ytd","weight":-0.3553}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"万邦德医药控股集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17671人(较上一季度减少90.28%)","perCapita":"32134股","listingDate":"2006-11-20","address":"浙江省湖州市吴兴区织里镇栋梁路1688号","registeredCapital":"61168万元","survey":" 万邦德医药控股集团股份有限公司的主营业务是集医药制造和医疗器械研发、生产、销售于一体。公司的主要产品是医药制造、医疗器械。","listedPrice":6.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST万邦(002082)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST万邦(002082)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST万邦,002082,ST万邦股票,ST万邦股票老虎,ST万邦股票老虎国际,ST万邦行情,ST万邦股票行情,ST万邦股价,ST万邦股市,ST万邦股票价格,ST万邦股票交易,ST万邦股票购买,ST万邦股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST万邦(002082)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST万邦(002082)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}